A blood-based liquid biopsy test detects early-onset colorectal cancer with strong diagnostic performance and high ...

The US Food and Drug Administration (FDA) approved Exact Sciences' next-generation multitarget stool DNA (mt-sDNA) test, Cologuard Plus, for use in adults 45 or older who are at average risk for ...

Blood-based screening for colorectal cancer (CRC) should only be used with patients who are not completing other endorsed screening options, according to a study. This study aimed to use a simulation ...

Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal cancer ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. “More than three out of four Americans who die from ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

Although the FDA approval of Guardant Health’s Shield blood test provides an appealing alternative to other colorectal cancer screening methods, the advantages and disadvantages should be highlighted ...

Colorectal cancer (CRC), more commonly called colon cancer, is currently the second-leading cause of cancer-related death in the U.S. But studies find it’s also highly treatable, especially if it’s ...

While screening for colorectal cancer (CRC) with a blood-based test would result in better outcomes than no screening at all, it would likely result in worse outcomes than currently available tests -- ...

The FDA has recently approved two new tests for colorectal cancer screenings. These tests are less invasive, and may encourage more patients to seek care. 1. At the beginning of October, the FDA ...